Washington D.C. — The American Society of Plastic Surgeons (ASPS) has issued an emergency white paper declaring the Clytia hemisphaerica medusa, a small jellyfish recently discovered to heal wounds within minutes without scarring, an "unprecedented biological threat" to the nation's multi-billion dollar cosmetic enhancement sector. Lobbyists are already pressuring federal agencies to classify the organism as an invasive species, citing its potential to "disrupt vital market ecosystems."
"For generations, we've built an economy around the human body's delightful inability to perfectly repair itself," stated Dr. Sterling Price, CEO of the ASPS, in a hastily called press conference. "Scars, wrinkles, age spots — these aren't flaws, they're investment opportunities. They're the raw material for innovation, for procedures, for entire lines of high-margin serums. To simply... heal? It’s profoundly anti-competitive." Dr. Price projected potential losses exceeding $200 billion annually if the jellyfish's regenerative properties were to become widely accessible, potentially rendering entire surgical specialties obsolete and devastating the industry’s robust M&A activity.
Sources within the ASPS indicate a rapid-response task force is exploring legislative avenues, including labeling jellyfish-derived healing agents as "unapproved biological weapons" or "performance-enhancing vanity drugs" requiring expensive, lifelong prescriptions. One proposal, currently gaining traction, suggests a federal mandate to genetically engineer human cells to produce scar tissue more reliably, ensuring a steady supply of cosmetic challenges. "We can't just let people walk around with flawless skin for free," an anonymous ASPS board member confessed. "Where's the incentive for innovation then? Where's the profit? This isn't healthcare; it's capitalism, and nature is clearly trying to corner the market."
The implications extend beyond plastic surgery, threatening the dermatology, anti-aging, and even tattoo removal industries, which together generate hundreds of billions in revenue from human imperfection. Beauty influencers, often dependent on showcasing before-and-after transformations, voiced concerns about their content pipelines drying up. "If everyone's perfect, what am I even supposed to sell?" lamented @GlowUpQueen4Eva on her private Discord channel. "My entire brand is about fixing things that suddenly won't need fixing."
Ultimately, the ASPS confirmed it is preparing a legal challenge based on the premise that jellyfish healing constitutes an unfair trade practice, claiming nature itself is "dumping free, high-quality epidermal repair onto the market without proper regulatory oversight or a single shareholder meeting."
